• head_banner_01

Factory source N Acetyl Carnitine Benefits - Semaglutide for Type 2 Diabetes – Gentolex

Short Description:


Product Detail

Product Tags

Related Video

Feedback (2)

With our loaded encounter and considerate services, we have now been recognized as a trustworthy supplier for lots of worldwide consumers for Benzaldehyde 2-Bromo-5-Chloro-, Methyllithium Lithium Bromide, Indacaterol Maleate, With a wide range, good quality, realistic charges and stylish designs,Our products and solutions are widely recognized and trusted by users and can fulfill continuously changing economic and social needs.
Factory source N Acetyl Carnitine Benefits - Semaglutide for Type 2 Diabetes – Gentolex Detail:

Product Detail

Name  Semaglutide
CAS number  910463-68-2
Molecular formula  C187H291N45O59
Molecular weight  4113.57754
EINECS Number  203-405-2

Synonyms

Sermaglutide; Semaglutide fandachem; Semaglutide impurity; Sermaglutide USP/EP; semaglutide; Sermaglutide CAS 910463 68 2; Ozempic, 

Description

Semaglutide is a new generation of GLP-1 (glucagon-like peptide-1) analogs, and semaglutide is a long-acting dosage form developed based on the basic structure of liraglutide, which has a better effect in the treatment of type 2 diabetes. Novo Nordisk has completed 6 Phase IIIa studies of semaglutide injection, and submitted a new drug registration application for semaglutide weekly injection to the U.S. Food and Drug Administration (FDA) on December 5, 2016. A Marketing Authorization Application (MAA) was also submitted to the European Medicines Agency (EMA).

Compared with liraglutide, semaglutide has a longer aliphatic chain and increased hydrophobicity, but semaglutide is modified with a short chain of PEG, and its hydrophilicity is greatly enhanced. After PEG modification, it can not only bind closely to albumin, cover the enzymatic hydrolysis site of DPP-4, but also reduce renal excretion, prolong the biological half-life, and achieve the effect of long circulation.

Application

Semaglutide is a long-acting dosage form developed based on the basic structure of liraglutide, which is more effective in treating type 2 diabetes.

Bioactivity

Semaglutide (Rybelsus, Ozempic, NN9535, OG217SC, NNC0113-0217) is a long-acting glucagon-like peptide 1 (GLP-1) analog, an agonist of GLP-1receptor, with a potential type 2 Therapeutic efficacy of diabetes mellitus (T2DM).

Quality System

In general, quality system and assurance is in place covering all stage of production of the finished product. Adequate manufacturing and control operations are performed in compliance with the approved procedures/ specifications. Change control and Deviation handling system is in place, and necessary impact assessment and investigation were conducted. Proper procedures are in place to ensure quality of product prior to release into the market.


Product detail pictures:

Factory source N Acetyl Carnitine Benefits - Semaglutide for Type 2 Diabetes – Gentolex detail pictures

Factory source N Acetyl Carnitine Benefits - Semaglutide for Type 2 Diabetes – Gentolex detail pictures


Related Product Guide:

Using a total scientific good quality management process, superior high quality and excellent faith, we get great name and occupied this field for Factory source N Acetyl Carnitine Benefits - Semaglutide for Type 2 Diabetes – Gentolex , The product will supply to all over the world, such as: Comoros, Korea, Riyadh, We adopt advanced production equipment and technology, and perfect testing equipment and methods to ensure our product quality. With our high-level talents, scientific management, excellent teams, and attentive service, our products are favored by domestic and foreign customers. With your support, we will build a better tomorrow!
  • We are really happy to find such a manufacturer that ensuring product quality at the same time the price is very cheap.
    5 Stars By Helen from Finland - 2017.02.28 14:19
    The product classification is very detailed that can be very accurate to meet our demand, a professional wholesaler.
    5 Stars By Doris from Japan - 2018.03.03 13:09
    Write your message here and send it to us